Thr58
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr58  -  Myc (human)

Site Information
kkFELLPtPPLsPsR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448496
Available spectra:  4 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 94 , 99 , 101 , 102 , 107 ) , flow cytometry ( 8 ) , immunoassay ( 4 ) , immunoprecipitation ( 10 , 14 , 16 , 17 , 34 , 37 , 104 , 105 ) , mass spectrometry ( 9 , 12 , 16 , 18 , 21 , 22 , 23 , 25 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 35 , 36 , 38 , 39 , 41 , 42 , 43 , 44 , 47 , 48 , 49 , 51 , 52 , 53 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 82 , 95 ) , mutation of modification site ( 5 , 8 , 14 , 17 , 20 , 34 , 35 , 37 , 50 , 54 , 79 , 80 , 83 , 84 , 86 , 88 , 90 , 91 , 92 , 94 , 96 , 97 , 98 , 99 , 102 , 103 , 104 , 105 , 107 , 108 ) , peptide sequencing ( 85 , 107 ) , phospho-antibody ( 4 , 5 , 6 , 7 , 8 , 10 , 15 , 19 , 24 , 37 , 46 , 50 , 79 , 81 , 83 , 84 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 ) , phosphoamino acid analysis ( 107 ) , phosphopeptide mapping ( 99 , 102 , 103 , 107 ) , western blotting ( 4 , 5 , 6 , 7 , 8 , 10 , 14 , 15 , 16 , 17 , 19 , 24 , 34 , 37 , 46 , 50 , 79 , 80 , 81 , 83 , 84 , 85 , 87 , 88 , 89 , 90 , 91 , 93 , 100 , 102 , 103 , 104 , 105 )
Disease tissue studied:
bone cancer ( 17 , 105 ) , Ewing's sarcoma ( 17 ) , brain cancer ( 81 ) , glioblastoma ( 81 ) , glioma ( 81 ) , breast cancer ( 5 , 8 , 22 , 23 , 24 , 37 , 43 , 46 , 54 ) , breast ductal carcinoma ( 22 ) , HER2 positive breast cancer ( 12 ) , luminal A breast cancer ( 12 ) , luminal B breast cancer ( 12 ) , breast cancer, surrounding tissue ( 12 ) , breast cancer, triple negative ( 12 , 22 ) , leukemia ( 47 , 85 , 87 , 100 ) , acute lymphocytic leukemia ( 87 ) , acute myelogenous leukemia ( 47 ) , chronic myelogenous leukemia ( 85 , 87 ) , liver cancer ( 10 , 46 ) , hepatocellular carcinoma ( 10 , 46 ) , lung cancer ( 7 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 36 , 80 , 83 ) , non-small cell lung cancer ( 7 , 29 , 30 , 31 , 33 , 36 , 83 ) , non-small cell lung adenocarcinoma ( 7 , 29 , 30 , 31 , 32 , 33 , 36 ) , non-small cell large cell lung carcinoma ( 30 ) , non-small cell squamous cell lung carcinoma ( 32 ) , small-cell lung cancer ( 27 , 28 ) , lymphoma ( 14 , 87 , 91 , 105 ) , Burkitt's lymphoma ( 87 , 91 , 105 ) , neuroblastoma ( 35 , 42 , 54 ) , ovarian cancer ( 17 , 22 ) , pancreatic cancer ( 15 , 93 ) , pancreatic carcinoma ( 15 , 93 ) , prostate cancer ( 6 , 50 ) , melanoma skin cancer ( 18 , 90 ) , fibrosarcoma of soft tissue ( 14 )
Relevant cell line - cell type - tissue:
293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 76 ) , 293 (epithelial) ( 6 , 8 , 17 , 24 , 37 , 50 , 73 , 74 , 79 , 86 , 88 , 93 , 96 , 97 , 98 , 100 , 103 ) , 293E (epithelial) ( 59 ) , 293GP (epithelial) [NPM-ALK (human), transfection] ( 75 ) , 2fTGH (fibroblast) ( 14 ) , 3T3 (fibroblast) ( 20 , 104 ) , A549 (pulmonary) ( 7 , 29 , 38 , 80 ) , A673 (muscle cell) ( 17 ) , Aspc1 (pancreatic) ( 93 ) , BC-1 (B lymphocyte) ( 85 ) , breast ( 12 , 22 ) , BT-20 (breast cell) ( 43 ) , BT-549 (breast cell) ( 43 ) , BxPC-3 (pancreatic) ( 93 ) , CA46 (B lymphocyte) ( 87 , 105 ) , Cal-12T (pulmonary) ( 36 ) , Calu-3 (pulmonary) ( 31 ) , Capan1 (pancreatic) ( 93 ) , COLO-320 (intestinal) ( 99 ) , COS (fibroblast) ( 99 , 103 , 107 ) , Daudi (B lymphocyte) ( 105 ) , DMS153 (pulmonary) ( 33 ) , DMS53 (pulmonary) ( 28 ) , DMS79 (pulmonary) ( 27 ) , DU 145 (prostate cell) ( 6 , 50 ) , ES (stem) ( 92 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 44 ) , Flp-In T-Rex-293 (epithelial) ( 44 ) , HA1E (embryonic) ( 19 ) , HCC15 (pulmonary) ( 32 ) , HCC1937 (breast cell) ( 43 ) , HCC44 (pulmonary) ( 36 ) , HCC827 (pulmonary) ( 31 ) , HEK293T (epithelial) ( 34 , 108 ) , HeLa (cervical) ( 4 , 6 , 9 , 16 , 21 , 41 , 60 , 62 , 64 , 66 , 67 , 68 , 69 , 70 , 71 , 77 , 82 , 84 , 95 , 98 , 105 ) , HL60 (myeloid) ( 87 , 100 ) , HLF (hepatic) ( 10 ) , HMEC (endothelial) ( 46 ) , HMLE (breast cell) ( 19 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 23 ) , HMLER ('stem, breast cancer') ( 23 ) , HPAC (pancreatic) ( 15 ) , HT1080 (fibroblast) ( 96 ) , HUES-9 ('stem, embryonic') ( 61 ) , Jurkat (T lymphocyte) ( 39 , 48 , 49 , 51 , 52 , 53 , 55 , 56 , 57 , 58 , 63 , 65 , 72 ) , K562 (erythroid) ( 41 , 87 ) , KG-1 (myeloid) ( 47 ) , LCL (lymphoblastoid) ( 85 ) , LNCaP (prostate cell) ( 50 ) , LOU-NH91 (squamous) ( 32 ) , lung ( 27 , 28 , 29 , 30 , 31 , 32 , 33 , 36 ) , LY2 (breast cell) ( 46 ) , M14-MEL (melanocyte) ( 90 ) , MC3T3 (preosteoblast) ( 101 ) , MCF-10A (breast cell) ( 24 , 37 , 54 ) , MCF-7 (breast cell) ( 24 , 43 , 46 ) , MCF10A1 (epithelial) ( 35 , 46 ) , MDA-MB-231 (breast cell) ( 5 , 8 , 43 , 46 ) , MDA-MB-453 (breast cell) ( 46 ) , MDA-MB-468 (breast cell) ( 43 ) , MEF (fibroblast) [HRas (human)] ( 89 ) , MEF (fibroblast) [Myc (mouse)] ( 90 ) , MEF (fibroblast) ( 8 ) , MIA PaCa-2 (pancreatic) ( 15 , 93 ) , mononuclear ( 87 ) , NB10 (neural crest) ( 42 ) , NCI-H128 (pulmonary) ( 27 ) , NCI-H1299 (pulmonary) ( 7 , 30 , 83 , 94 ) , NCI-H1355 (pulmonary) ( 29 ) , NCI-H1417 (pulmonary) ( 27 ) , NCI-H1437 (pulmonary) ( 33 , 36 ) , NCI-H1650 (pulmonary) ( 31 ) , NCI-H1666 (pulmonary) ( 36 ) , NCI-H1703 (squamous) ( 32 ) , NCI-H1734 (pulmonary) ( 30 ) , NCI-H1792 (pulmonary) ( 29 ) , NCI-H1944 (pulmonary) ( 30 ) , NCI-H1975 (pulmonary) ( 31 ) , NCI-H2073 (pulmonary) ( 32 , 33 ) , NCI-H209 (pulmonary) ( 27 , 33 ) , NCI-H2106 (pulmonary) ( 31 ) , NCI-H23 (pulmonary) ( 29 ) , NCI-H2342 (pulmonary) ( 32 ) , NCI-H2405 (pulmonary) ( 36 ) , NCI-H358 (pulmonary) ( 30 ) , NCI-H441 (pulmonary) ( 29 ) , NCI-H446 (pulmonary) ( 28 ) , NCI-H460 (pulmonary) ( 30 , 83 ) , NCI-H524 (pulmonary) ( 27 ) , NCI-H526 (pulmonary) ( 28 ) , NCI-H69 (pulmonary) ( 28 , 94 ) , NCI-H82 (pulmonary) ( 28 , 94 ) , NCI-H838 (pulmonary) ( 33 ) , NPC (neural crest) ( 42 ) , ovary ( 22 ) , PANC-1 (pancreatic) ( 15 ) , pancreas ( 93 ) , PC9 (pulmonary) ( 7 ) , Rael ( 105 ) , Raji (B lymphocyte) ( 105 ) , RAMOS (B lymphocyte) ( 91 ) , REF52 (fibroblast) ( 102 ) , Reh (B lymphocyte) ( 87 ) , Saos-2 (bone cell) ( 101 ) , SH-SY5Y (neural crest) ( 25 ) , SHEP (neuron) ( 35 , 54 ) , SKBr3 (breast cell) ( 46 ) , SKOV-3 (ovarian) ( 17 ) , SNU-475 (hepatic) ( 46 ) , ST486 (B lymphocyte) ( 105 ) , SUM159 (breast cell) ( 5 ) , SUP-B15 (B lymphocyte) ( 87 ) , SW1990 (pancreatic) ( 15 ) , TIME (endothelial) ( 84 ) , U-251 MG (glial) ( 81 ) , U-937 (myeloid) ( 14 , 105 ) , U2OS (bone cell) ( 105 ) , WM239A (melanocyte) ( 18 )

Upstream Regulation
Regulatory protein:
BAF53A (human) ( 5 ) , GLIPR1 (human) ( 50 ) , HRas (human) ( 19 ) , IKKA (human) ( 6 ) , IKKB (human) ( 6 ) , LANA (herpesvirus) ( 84 , 85 ) , MICALL2 (human) ( 7 ) , PARK2 (human) ( 4 ) , PPP2R5A (human) ( 88 ) , PPP2R5B (human) ( 88 ) , PPP2R5C (human) ( 88 ) , PPP2R5D (human) ( 88 ) , PPP2R5E (human) ( 88 ) , RHOA (human) ( 19 ) , SET (human) ( 80 )
Putative in vivo kinases:
GSK3A (human) ( 98 , 99 , 100 ) , GSK3B (human) ( 4 , 5 , 50 , 97 , 102 )
Kinases, in vitro:
ERK2 (human) ( 106 ) , GSK3B (human) ( 97 ) , JNK3 (human) ( 106 )
Phosphatases, in vitro:
EYA1 (human) ( 8 )
Treatments:
2-deoxyglucose ( 78 ) , angiotensin_2 ( 76 ) , BMS-345541 ( 6 ) , bortezomib ( 91 ) , Bz-423 ( 91 ) , ceramide ( 80 ) , EGF ( 9 , 77 ) , enzastaurin ( 81 ) , glucocorticoid ( 101 ) , GSK-3_inhibitor_II ( 98 ) , H2O2 ( 4 ) , KCl ( 100 ) , lactacystin ( 85 ) , LIF ( 92 ) , lithium ( 79 , 99 , 100 ) , LY294002 ( 19 , 93 ) , MG132 ( 93 ) , PD98059 ( 94 ) , SB216763 ( 91 ) , SB415286 ( 91 ) , SCH772984 ( 15 ) , selumetinib ( 18 ) , serum ( 100 ) , serum_starvation ( 100 ) , siRNA ( 85 ) , staurosporine ( 94 ) , U0126 ( 19 , 77 ) , vemurafenib ( 18 ) , Y27632 ( 19 )

Downstream Regulation
Effects of modification on Myc:
intracellular localization ( 99 , 100 ) , molecular association, regulation ( 10 , 16 , 34 , 37 , 97 , 98 , 103 ) , phosphorylation ( 80 ) , protein conformation ( 8 ) , protein degradation ( 4 , 5 , 6 , 7 , 8 , 17 , 37 , 50 , 79 , 80 , 83 , 84 , 91 , 92 , 97 , 98 , 99 , 101 , 102 , 103 , 104 , 105 ) , protein stabilization ( 10 , 46 ) , ubiquitination ( 5 , 7 , 17 , 50 , 105 )
Effects of modification on biological processes:
apoptosis, induced ( 6 , 54 ) , autophagy, induced ( 4 ) , carcinogenesis, induced ( 10 , 46 ) , carcinogenesis, inhibited ( 5 , 35 ) , cell cycle regulation ( 7 , 8 ) , cell differentiation, altered ( 92 ) , cell growth, altered ( 20 ) , cell growth, induced ( 10 ) , cell growth, inhibited ( 5 , 6 , 7 , 54 ) , transcription, altered ( 107 ) , transcription, induced ( 34 ) , transcription, inhibited ( 4 , 5 , 6 , 7 , 35 )
Induce interaction with:
AurA (human) ( 10 ) , CDC73 (human) ( 16 ) , FBXW7 (human) ( 97 , 98 ) , PIN1 (human) ( 34 ) , SH2BP1 (human) ( 16 )
Inhibit interaction with:
DNA ( 37 ) , FBXW7 (human) ( 8 ) , TUBA4A (human) ( 103 )

Disease / Diagnostics Relevance
Relevant diseases:
breast cancer ( 46 ) , AIDS-related lymphoma ( 85 , 105 ) , B cell lymphoma ( 105 ) , Burkitt's lymphoma ( 103 , 104 , 105 )

References 

1

Scarpa M, et al. (2021) Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication. Oncotarget 12, 1763-1779
34504649   Curated Info

2

Zhu L, et al. (2021) Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR tyrosine kinase inhibitor, osimertinib. Cancer Res
34289988   Curated Info

3

Waters AM, et al. (2021) Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Rep 35, 109291
34192548   Curated Info

4

Zhang C, et al. (2021) Oxidative stress-induced mitophagy is suppressed by the miR-106b-93-25 cluster in a protective manner. Cell Death Dis 12, 209
33627622   Curated Info

5

Jian Y, et al. (2021) Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer. J Exp Clin Cancer Res 40, 56
33541412   Curated Info

6

Moser B, et al. (2021) The inflammatory kinase IKKα phosphorylates and stabilizes c-Myc and enhances its activity. Mol Cancer 20, 16
33461590   Curated Info

7

Min P, et al. (2020) MICAL-L2 Is Essential for c-Myc Deubiquitination and Stability in Non-small Cell Lung Cancer Cells. Front Cell Dev Biol 8, 575903
33520979   Curated Info

8

Li J, et al. (2017) EYA1's Conformation Specificity in Dephosphorylating Phosphothreonine in Myc and Its Activity on Myc Stabilization in Breast Cancer. Mol Cell Biol 37
27795300   Curated Info

9

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

10

Dauch D, et al. (2016) A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nat Med 22, 744-53
27213815   Curated Info

11

Rabellino A, et al. (2016) PIAS1 Promotes Lymphomagenesis through MYC Upregulation. Cell Rep 15, 2266-78
27239040   Curated Info

12

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

13

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

14

Bahram F, et al. (2016) Interferon-γ-induced p27KIP1 binds to and targets MYC for proteasome-mediated degradation. Oncotarget 7, 2837-54
26701207   Curated Info

15

Hayes TK, et al. (2016) Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell 29, 75-89
26725216   Curated Info

16

Jaenicke LA, et al. (2016) Ubiquitin-Dependent Turnover of MYC Antagonizes MYC/PAF1C Complex Accumulation to Drive Transcriptional Elongation. Mol Cell 61, 54-67
26687678   Curated Info

17

Mei Z, et al. (2015) FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity. J Biol Chem 290, 16202-14
25944903   Curated Info

18

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

19

Watnick RS, et al. (2015) Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells. Oncogene 34, 2823-35
25109329   Curated Info

20

Chakraborty AA, et al. (2015) A common functional consequence of tumor-derived mutations within c-MYC. Oncogene 34, 2406-9
24998853   Curated Info

21

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

22

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

23

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

24

Puustinen P, et al. (2014) CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. J Cell Biol 204, 713-27
24590173   Curated Info

25

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

26

Kalkat M, et al. (2014) Identification of c-MYC SUMOylation by Mass Spectrometry. PLoS One 9, e115337
25522242   Curated Info

27

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

28

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

29

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

30

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

31

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

32

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

33

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

34

Sanchez-Arévalo Lobo VJ, et al. (2013) Dual regulation of Myc by Abl. Oncogene 32, 5261-71
23318434   Curated Info

35

Wasylishen AR, et al. (2013) MYC Phosphorylation at Novel Regulatory Regions Suppresses Transforming Activity. Cancer Res 73, 6504-15
24030976   Curated Info

36

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

37

Farrell AS, et al. (2013) Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis. Mol Cell Biol 33, 2930-49
23716601   Curated Info

38

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

39

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

40

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

41

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

42

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

43

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

44

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

45

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

46

Zhang X, et al. (2012) Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression. Proc Natl Acad Sci U S A 109, 2790-5
21808024   Curated Info

47

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

48

Mulhern D (2012) CST Curation Set: 13339; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

49

Mulhern D (2012) CST Curation Set: 13340; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

50

Li L, et al. (2011) GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res 71, 7694-704
22025562   Curated Info

51

Mulhern D (2011) CST Curation Set: 12640; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

52

Mulhern D (2011) CST Curation Set: 12641; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

53

Mulhern D (2011) CST Curation Set: 12642; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

54

Wasylishen AR, et al. (2011) New model systems provide insights into Myc-induced transformation. Oncogene 30, 3727-34
21441954   Curated Info

55

Mulhern D (2011) CST Curation Set: 12440; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

56

Mulhern D (2011) CST Curation Set: 12442; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

57

Mulhern D (2011) CST Curation Set: 12443; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

58

Guo A (2011) CST Curation Set: 12018; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

59

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

60

Guo A (2011) CST Curation Set: 11453; Year: 2011; Biosample/Treatment: cell line, HeLa/nocodazole &'||' pervanadate; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

61

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

62

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

63

Possemato A (2010) CST Curation Set: 10875; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

64

Zhou J (2010) CST Curation Set: 10712; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

65

Possemato A (2010) CST Curation Set: 10722; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

66

Zhou J (2010) CST Curation Set: 10710; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

67

Zhou J (2010) CST Curation Set: 10713; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

68

Zhou J (2010) CST Curation Set: 10691; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

69

Zhou J (2010) CST Curation Set: 10689; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

70

Zhou J (2010) CST Curation Set: 10685; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

71

Zhou J (2010) CST Curation Set: 10686; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

72

Possemato A (2010) CST Curation Set: 10157; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

73

Guo A (2010) CST Curation Set: 9968; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

74

Guo A (2010) CST Curation Set: 9970; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

75

Wu F, et al. (2010) Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma. Mol Cell Proteomics 9, 1616-32
20393185   Curated Info

76

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

77

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

78

Zhong D, et al. (2009) The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R. J Biol Chem 284, 23225-33
19574224   Curated Info

79

Arnold HK, et al. (2009) The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc. EMBO J 28, 500-12
19131971   Curated Info

80

Mukhopadhyay A, et al. (2009) Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J 23, 751-63
19028839   Curated Info

81

Kotliarova S, et al. (2008) Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res 68, 6643-51
18701488   Curated Info

82

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

83

Seo HR, et al. (2008) Cdk5-mediated phosphorylation of c-Myc on Ser-62 is essential in transcriptional activation of cyclin B1 by cyclin G1. J Biol Chem 283, 15601-10
18408012   Curated Info

84

Liu J, Martin HJ, Liao G, Hayward SD (2007) The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. J Virol 81, 10451-9
17634226   Curated Info

85

Bubman D, Guasparri I, Cesarman E (2007) Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene 26, 4979-86
17310999   Curated Info

86

Fujii M, et al. (2006) SNIP1 is a candidate modifier of the transcriptional activity of c-Myc on E box-dependent target genes. Mol Cell 24, 771-83
17157259   Curated Info

87

Malempati S, et al. (2006) Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias. Leukemia 20, 1572-81
16855632   Curated Info

88

Arnold HK, Sears RC (2006) Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol Cell Biol 26, 2832-44
16537924   Curated Info

89

Huang M, Kamasani U, Prendergast GC (2006) RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3. Oncogene 25, 1281-9
16247449   Curated Info

90

Benassi B, et al. (2006) c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell 21, 509-19
16483932   Curated Info

91

Sundberg TB, et al. (2006) The immunomodulatory benzodiazepine Bz-423 inhibits B-cell proliferation by targeting c-myc protein for rapid and specific degradation. Cancer Res 66, 1775-82
16452238   Curated Info

92

Cartwright P, et al. (2005) LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development 132, 885-96
15673569   Curated Info

93

Asano T, et al. (2004) The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 23, 8571-80
15467756   Curated Info

94

Jin Z, Gao F, Flagg T, Deng X (2004) Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J Biol Chem 279, 40209-19
15210690   Curated Info

95

Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5
15302935   Curated Info

96

Sato S, Fujita N, Tsuruo T (2004) Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway. J Biol Chem 279, 33759-67
15175348   Curated Info

97

Welcker M, et al. (2004) The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A 101, 9085-90
15150404   Curated Info

98

Yada M, et al. (2004) Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 23, 2116-25
15103331   Curated Info

99

Gregory MA, Qi Y, Hann SR (2003) Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 278, 51606-12
14563837   Curated Info

100

Kamemura K, Hayes BK, Comer FI, Hart GW (2002) Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: alternative glycosylation/phosphorylation of THR-58, a known mutational hot spot of c-Myc in lymphomas, is regulated by mitogens. J Biol Chem 277, 19229-35
11904304   Curated Info

101

Smith E, Coetzee GA, Frenkel B (2002) Glucocorticoids inhibit cell cycle progression in differentiating osteoblasts via glycogen synthase kinase-3beta. J Biol Chem 277, 18191-7
11877389   Curated Info

102

Sears R, et al. (2000) Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14, 2501-14
11018017   Curated Info

103

Niklinski J, et al. (2000) Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma. Mol Cell Biol 20, 5276-84
10866684   Curated Info

104

Gregory MA, Hann SR (2000) c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 20, 2423-35
10713166   Curated Info

105

Bahram F, von der Lehr N, Cetinkaya C, Larsson LG (2000) c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95, 2104-10
10706881   Curated Info

106

Noguchi K, et al. (1999) Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J Biol Chem 274, 32580-7
10551811   Curated Info

107

Gupta S, Seth A, Davis RJ (1993) Transactivation of gene expression by Myc is inhibited by mutation at the phosphorylation sites Thr-58 and Ser-62. Proc Natl Acad Sci U S A 90, 3216-20
8386367   Curated Info

108

Gao R, et al. E3 Ubiquitin Ligase RLIM Negatively Regulates c-Myc Transcriptional Activity and Restrains Cell Proliferation. PLoS One 11, e0164086
27684546   Curated Info